logo-loader

Noxopharm raises $10.8 million to accelerate anti-cancer drug development

Published: 11:22 23 Mar 2018 AEDT

australian dollar notes
Growing market confidence in the company's technology

Noxopharm Limited (ASX:NOX) has raises $10.8 million via the placement of shares to sophisticated and institutional investors at 90 cents each.

The company will use the funds to accelerate the clinical development of its front-line anti-cancer drug, NOX66.

Noxopharm chairman Peter Marks said: “The offer was heavily oversubscribed, which meant having to scale-back share allocations.

“We take this as a sign of the growing market confidence in our technology and revenue opportunity”

Enhancing an experimental anti-cancer drug

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil and to enhance its drug-like behaviour.

Noxopharm’s objectives is to generate clear evidence of the anticancer activity of NOX66 by the end of this year.

The company is also determining the nature of a phase III registration study which is anticipated to commence in 2019.

READ: Noxopharm attracts $4 million for three drugs targeting unmet medical needs

The company recently raised $4 million via the issue of convertible notes for its U.S.-based subsidiary, Nyrada Inc.

The new funds are to be applied for the development of three drug assets:

• NYX-104 - a first-in-class neuroprotectant drug designed to minimise brain damage following stroke and traumatic brain injury such as concussion (e.g. sporting injuries);

• NYX-205 - a first-in-class anti-inflammatory drug designed to treat the condition of peripheral neuropathy, a painful condition affecting about 40% of cancer patients receiving certain common chemotherapies; and

• NYX-330 - a first-in-class small molecule PCSK9-inhibitor intended to treat high blood LDL cholesterol levels.

Phase I study is targeted to commence in mid-2019

Each of these three drugs is currently in pre-clinical development. The respective clinical indications have been identified and the first phase I study is targeted to commence in mid-2019.

Combined with its existing cash position and the anticipated research and development rebate, Noxopharm now has the necessary funds to carry out its business objectives for the remainder of 2018.

Noxopharm talks partnership with Hudson Institute of Medical Research

Noxopharm Ltd (ASX:NOX, OTC:NOXOF) chief executive officer Dr Gisela Mautner joins Proactive alongside Associate Professor Michael Gantier from the Hudson Institute of Medical Research to discuss their partnering on the SOF-VAC mRNA vaccine enhancer. They’re investigating the potential for Sofra...

on 12/10/23